Dallas TX 10/26/2009 8:06:25 AM
News / Business

RVGD, BZCN, GRDO, XMDC, AEMD, PDMI OTCPicks.com Stocks to Watch for Monday, October 26th

Visit http://www.otcpicks.com/microcap.htm today to join this growing community.

Our Stocks to Watch tomorrow include Revenge Designs Inc. (OTC: RVGD), BizAuctions Inc. (OTC: BZCN), Guard Dog Inc. (OTC: GRDO), XTend Medical Corp. (OTC: XMDC), Aethlon Medical Inc. (OTCBB: AEMD) and Paradigm Medical Industries Inc. (OTCBB: PDMI).

 

REVENGE DESIGNS INCORPORATED (OTC: RVGD)

"Up 150.00% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/RVGD.php

 

Revenge Designs Inc., a specialty car designer and production assembler, is headquartered in a facility in North Eastern Indiana. Mr. Peter Collorafi, President and CEO of Revenge Designs Inc., is a car designer from Queensland, Australia. Mr. Collorafi has been designing and installing custom modifications for factory produced vehicles since 1980. The Revenge GTM-R Super Car is the company's first production vehicle. Their other products include the Revenge Solstice, Revenge Ridgeline, and the award winning Revenge GTO.

 

RVGD News:

 

October 23 - Revenge Designs Inc. Update to Shareholders

 

Revenge Designs Inc. (OTC: RVGD) announces that it is on track with the Verde Super car concept vehicle, marked for completion mid December 2009.

 

DuPont registry publishing will be the first magazine to have the scoop on the Revenge Verde Super car renderings in their December 2009 issue. This also kicks off a twelve month advertising campaign with this prestigious automotive magazine.

 

Revenge has received conformation of our site for the release of the Verde Super car at the North American International Auto Show, held in Detroit, MI January 11th through 24th, 2010 at the Cobo Center.

 

Negotiations are still ongoing with Henry County Ohio Revolving loan committee and also various private placement investors who have come to the table with assisting Revenge to locate the first Certified Installation Center and training facility in Ohio which will also house management and marketing staff.

 

Mr. Peter Collorafi, CEO/President of Revenge, will be attending SEMA (Specialty Engineering Manufactures Association) along with Mr. Douglas Palmear, owner of HP2G in November. Mr. Collorafi stated, "We are all very excited with the interest in the installation centers in California and looking forward to face to face meetings with all interested parties." Mr. Palmear will also be speaking at the opening of SEMA to discuss all aspects of the HP2G Hybrid V8 engine technology, which is offered as an engine option in the Revenge Super car. The HP2G engine is the first Hybrid assisted V8 engine, supplying its own energy recharge to support the E85 fuel. Engine specifications will be announced after the SEMA release. There will also be an engine on display at the Detroit Auto Show at the Revenge Exhibit.

 

BIZAUCTIONS INCORPORATED (OTC: BZCN)

"Up 62.50% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/BZCN.php

 

BizAuctions, Inc. is a prime provider of commercial eBay liquidation services for excess inventory, overstock items, and returns. Our clients have included some of the Nation's leading retail names at the forefront of their industries. BizAuctions addresses the $60 billion excess inventory problem for clients by sending trucks to pick up pallets of excess inventory, selling the inventory on eBay, and collecting payment. We provide our clients with a new sales channel to generate additional revenue on excess inventory, while at the same time freeing up their valuable storage and retail space. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate its excess inventory on eBay.

 

BZCN News:

 

August 12 - AmeriResource Plans to Create Overstock.com-like Retail Web Site to Boost BizAuctions Revenue

 

AmeriResource Technologies, Inc. (OTC: ARIO) announced it is in the preliminary stages of creating a web site designed to sell certain discounted goods through a web platform that is intended to resemble an Overstock.com like web site.

 

Delmar Janovec, AmeriResource, CEO, noted, "BizAuctions (OTC: BZCN) primarily sells its products through its eBay platform and clothing articles through its newly opened retail store, Lucky 7's, in Southern California. Selling certain products directly to the public on a new web site may be a way to boost revenues and improve margins. We already have the staff and warehouse space to accommodate selling directly to the public so the only real additional cost will be the creation of the web site."

 

Mr. Janovec continued, "We understand that in order to significantly boost revenues it is very important that BizAuctions begins brand building by initiating a significant marketing campaign through traditional channels such a billboards, TV, pay per click ads, obtaining celebrity endorsements and the like. Over the coming months, AmeriResource and its subsidiaries are going to explore its options in launching a national marketing effort. It is clear from such penny stock companies like SpongeTech traded on the OTCBB that traditional marketing not only helps build your brand but also appears to have a positive impact on liquidity and share value."

 

"AmeriResource also is in the process of updating its own web site and subsidiary web sites as well as its ATTO Solutions web site which has dated information. We are committed to delivering up to date and accurate information to potential customers and investors alike. Management is working diligently to bring AmeriResource filings current with the SEC and revamping our web site to be in compliance with the current information requirements," concluded Janovec.

 

GUARD DOG INCORPORATED (OTC: GRDO)

"Up 40.35% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/GRDO.php

 

Guard Dog, Inc. is rapidly accelerating to become an industry leader in the rapidly growing field of Identity Theft Protection. The company strives to serve the growing needs of consumers throughout the United States. Guard Dog, Inc. is an aggregator and supplier of a broad spectrum of services similar to that of other industry leaders including LifeLock. However, in addition to offering a similar suite of services to that of competitors, Guard Dog, Inc. provides downloadable applications, which will notify a customer through a computer alert notification in the event of any identity theft red flags become triggered.

 

GRDO News:

 

October 13 - Guard Dog Celebrates Upgraded Website And Marketing Blitz

 

Guard Dog Inc. (OTC: GRDO) announced that Guard Dog ID, LLC, a growing leader in identity theft prevention services has completed the long awaited technical support upgrades and enhancements to its web based infrastructure. The company is celebrating this greatly anticipated event with the launch of a new marketing blitz. “A slew of upgrades – enhancing everything from simple aesthetics to complex behind the scenes software, has fortified Guard Dog’s infrastructure with cutting edge technology and a new bold image, revitalizing our influence in the identity theft protection market,” stated James Watson, President and CEO of Guard Dog.

 

“The completion of these upgrades and enhancements answer many long-standing issues from previous beta testing. A few of the new market-leading enhancements that will propel the company to the forefront as an industry leader include The MyGuardDog Dashboard: an expandable and user friendly customer driven account management tool with built–in affiliate marketing features; data security utilizing 256-bit AES Security Data Encryption with certified Extended Validation SSL and PCI-DSS Compliance checks. We have focused tremendous resources to ensure that any and all data transmitted through or stored on Guard Dog Servers is secured by the most stringent security standards of any online merchant,” continued Watson.

 

In conjunction with continual promotions running throughout the companies marketing blitz, new members can sign up for our newly introduced family plans for as low as $19.95 a month, our individual identity protection plans for as low as $9.95 a month, and join our new affiliate partner program by simply visiting www.guarddogid.com.

 

Further updates regarding our marketing blitz and Corporate Affinity Program will be released in weeks to come.

 

XTEND MEDICAL CORPORATION (OTC: XMDC)

"Up 37.50% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/XMDC.php 

 

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.

 

XMDC News:

 

October 22 - XTend Medical Updates Shareholders on Merger and Company's Progress

 

Management to Travel to Korea to Finalize Merger

 

XTend Medical Corp. (OTC: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the company's progress on merger and company's progress:

 

"XTend would like to update our shareholders on our progress to date. Mr. Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend. The meetings were very positive and included several aspects in the manufacturing process and the business model moving forward. I personally want to thank Mr. Lee for his dedication and efforts in moving the merger forward. The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger. We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company. While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.

 

The combined efforts of the seasoned technical team in Korea with the management in the U.S. will insure that the BioHarp device will become the standard in medical diagnosis. Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally. As we move forward, these opportunities will be explored and if they benefit the company, we will press forward on a working relationship.

 

As to the BioHarp unit itself, I would like to reiterate a few areas that make this device unique:

 

1. The BioHarp requires a pre-scan of the patient in order to get a baseline reading. This baseline reading is not based solely on a set of standards in the medical sector. These individualized baselines are established from the patient's own cellular makeup and further solidify how the BioHarp sets itself apart from any present of future competitors.

 

2. The BioHarp device is completely portable. Unlike CT Scanners and other large pieces of equipment that remain stationary, the BioHarp can travel to where the patients are. The unit is perfect for rural areas, battlefields, or other outlying areas that would benefit by having the BioHarp as part of their healthcare service.

 

3. BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.

 

4. The dedication Mr. Lee has spent on this device over the past 14 years is truly incredible. His vision for this device has proven instrumental in the development of the BioHarp. His technical staff has, and continues t, spend countless hours perfecting this product and we feel honored to become part of this exciting and truly unique product.

 

In closing, I would like to thank all of our shareholders for being patient as we close this merger. Mr. Lee and I have worked continuously over the past two years to insure you, as shareholders, will reap the benefits of being part of something we're very proud of. The future is very bright for this company and through hard work and dedication, the BioHarp will flourish and become the leading diagnostic device in the global medical community," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

 

AETHLON MEDICAL INCORPORATED (OTCBB: AEMD)

"Up 36.13% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/AEMD.php

 

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

 

AEMD News:

 

October 22 - Aethlon Medical Establishes Exosome Sciences, Inc.

 

Aethlon Medical, Inc. (OTCBB: AEMD) announced that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company. ESI will seek to leverage the recent discovery that the Hemopurifier®, a medical device developed by Aethlon Medical as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. Aethlon Medical, Inc. will contribute into ESI all exosome-related patents and patents pending.

 

Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc. said, "The ability to reduce circulating exosomes would likely reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy, thus positioning ESI to participate in the $43 billion cancer therapy market. ESI also plans to advance exosome diagnostic and research services, and explore recently discovered opportunities to address exosomes in disease conditions beyond cancer."

 

In the last year alone, an increasing number of research driven science publications reveal that exosomes have implications in inflammatory conditions including Sepsis, bacterial infections including Tuberculosis (TB), autoimmune conditions such as Rheumatoid Arthritis, and neurological and neurodegenerative diseases such as Alzheimer's disease The growth in the exosome industry is further evidenced by published research and citations increasing from 140 articles in 2001 to 1,160 articles and citations in 2008.

 

"ESI allows us to leverage the previously unrecognized value of our non-infectious disease research into a new asset that positions us to be an important participant in the emerging exosome industry. We also maintain the option of installing an independent management team at ESI and if appropriate in the future, may spin out part or all of ESI as a means to achieve fuller valuation for Aethlon Medical shareholders," concluded Joyce.

 

A recent publication entitled, "Exosomes as a Tumor Immune Escape Mechanism: Possible Therapeutic Implications" discusses the potential for the Hemopurifier® to become the first therapeutic strategy to inhibit the immune suppression caused by tumor secreted exosomes.

 

PARADIGM MEDICAL INDUSTRIES INCORPORATED (OTCBB: PDMI)

"Up 35.71% on Friday"

 

Detailed Quote: http://www.otcpicks.com/quotes/PDMI.php 

 

Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. Paradigm has the only patented technology utilizing photon laser for cataract removal. The Company is poised to capture a niche market within the Glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.

 

PDMI News:

 

June 1 - Paradigm Medical Announces Plans to Release Its New Corneal Topographer, the Paravue, in the United States Market

 

Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced that the Company will soon begin to introduce the first of its four new ophthalmic diagnostic devices, the Paravue, during the remainder of 2009. The Paravue is a sophisticated topographer utilizing Placido Disk Technology and an advanced software to provide accurate and detailed analysis of the anterior corneal surface.

 

Corneal topography — also known as videokeratography or corneal mapping — represents a significant advance in the measurement of the corneal curvature. Most corneal topographers evaluate 8,000 to 10,000 specific points across the entire corneal surface. By contrast, the Paravue processes more than 100,000 points. It also offers corneal wave front analysis with 2, 3 or 4 maps available for comparison.

 

The Paravue provides both a qualitative and quantitative evaluation of corneal curvature. It does so by utilizing a big placido disk with 24 concentric rings, which project onto the cornea to create a virtual image. The device compares this image to the target size, and the computer then calculates the corneal curvature. Advanced features including advanced rings editing, variable scales, refractive power map and more make the Paravue a valuable tool in the optometric and ophthalmic clinics.

 

"The addition of the Paravue to our existing ophthalmic product line fills an important segment that was missing," said Paradigm Medical President, Stephen Davis. "We are excited to offer not just another topographer, but one with many impressive features and incredibly friendly software that provides ease of use, flexible mapping and accuracy."

 

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com have been compensated eight thousand dollars by a third Party (Geneva Bancorp) for MEVT advertising and promotional services.